News Search Results
Dec 09, 2025, 08:00 ET Ginkgo Bioworks partners on Deep Origin-led team to develop new tools for predicting drug safety
and other expectations, and to identify and realize additional business opportunities, (iii) the risk of downturns in demand for products using synthetic biology, (iv) the uncertainty regarding the demand for passive monitoring programs and biosecurity services, (v) changes to the biosecurity industry,
More news about: Ginkgo Bioworks
Dec 08, 2025, 10:45 ET Precision Fermentation Market is expected to generate a revenue of USD 34.2 Billion by 2032, Globally, at 40.1% CAGR: Verified Market Research®
competitive advantage.2. Advancements in Synthetic Biology and Fermentation TechnologiesTechnological innovation remains a major accelerator for the Precision Fermentation Market. Modern synthetic biology platforms enable manufacturers to design highly efficient microbial
More news about: Verified Market Research
Dec 05, 2025, 08:33 ET Ginkgo Bioworks Selected by PNNL to Deliver a Modular, High‑Throughput Phenotyping Platform for DOE's M2PC
business opportunities, including with respect to our solutions and tools offerings, (iv) the risk of downturns in demand for products using synthetic biology, (v) the uncertainty regarding the demand for passive monitoring programs and biosecurity services, (vi) changes to the biosecurity industry,
More news about: Ginkgo Bioworks
Dec 03, 2025, 18:45 ET CABIO présente l'innovation nutritionnelle à tous les stades de la vie au salon Fi Europe 2025 Paris, à l'occasion de l'ouverture de son nouveau siège mondial.
chinoise, présente son portefeuille complet d'ingrédients nutritionnels tout en annonçant l'ouverture officielle de son nouveau siège mondial, le Synthetic Biology Innovation Hub de Wuhan, marquant ainsi un pas en avant décisif et précurseur dans l'avenir de la biologie synthétique. Un nouveau siège
More news about: CABIO Biotech (Wuhan) Co, Ltd
Dec 03, 2025, 12:11 ET CABIO präsentiert auf der Fi Europe 2025 in Paris Innovationen im Bereich Lebensphasenernährung und eröffnet gleichzeitig seinen neuen globalen Hauptsitz
umfassendes Portfolio an Nahrungsergänzungsmitteln und gibt gleichzeitig die offizielle Eröffnung seines neuen globalen Hauptsitzes – des Wuhan Synthetic Biology Innovation Hub – bekannt, der einen entscheidenden Sprung nach vorne bei der Erschließung der Zukunft der synthetischen Biologie darstellt.
More news about: CABIO Biotech (Wuhan) Co, Ltd
Dec 03, 2025, 09:00 ET CABIO Showcases Life-Stage Nutrition Innovation at Fi Europe 2025 Paris as the New Global Headquarter Opens
announcing the official opening of its new Global Headquarter-Wuhan Synthetic Biology Innovation Hub, marking a pivotal leap forward in pioneering the future of synthetic biology.New Global Headquarter Strengthens Innovation FoundationCABIO's state-of-the-art
More news about: CABIO Biotech (Wuhan) Co, Ltd
Dec 03, 2025, 04:01 ET CABIO Showcases Life-Stage Nutrition Innovation at Fi Europe 2025 Paris as the New Global Headquarter Opens
portfolio while simultaneously announcing the official opening of its new Global Headquarter-Wuhan Synthetic Biology Innovation Hub, marking a pivotal leap forward in pioneering the future of synthetic biology. New Global Headquarter Strengthens Innovation FoundationCABIO's state-of-the-art
More news about: CABIO Biotech (Wuhan) Co, Ltd
Nov 26, 2025, 08:00 ET mAIbe and LenioBio announce a new strategic collaboration aimed at accelerating the discovery and experimental validation of next-generation monoclonal antibodies
mAIbemAIbe is a biotechnology company focused on AI-guided monoclonal antibody design. Its platform combines physics-informed generative AI and synthetic biology to develop precise, cost-effective antibodies targeting viral and bacterial pathogens. Based in Rome, Italy, mAIbe operates at the convergence
More news about: LenioBio
Nov 26, 2025, 03:00 ET mAIbe and LenioBio announce a new strategic collaboration aimed at accelerating the discovery and experimental validation of next-generation monoclonal antibodies
mAIbemAIbe is a biotechnology company focused on AI-guided monoclonal antibody design. Its platform combines physics-informed generative AI and synthetic biology to develop precise, cost-effective antibodies targeting viral and bacterial pathogens. Based in Rome, Italy, mAIbe operates at the convergence
More news about: LenioBio
Nov 20, 2025, 09:43 ET ViVac Appoints Keren Leshem as Chief Executive Officer, Strengthening Leadership to Advance RNA-Lipid Nanoparticle Immunotherapy Platform
JERUSALEM, Nov. 20, 2025 /PRNewswire/ -- ViVac Pharma Ltd., a pioneering synthetic biology company advancing RNA–Lipid Nanoparticle (LNP) immunotherapies, announces the appointment of Keren Leshem as Chief Executive
More news about: ViVac Pharma Ltd.
Nov 18, 2025, 08:00 ET Ginkgo Bioworks Partners on Illinois-Led Team to Develop Innovative New Treatments for Oral Health
business opportunities, including with respect to our solutions and tools offerings, (iv) the risk of downturns in demand for products using synthetic biology, (v) the uncertainty regarding the demand for passive monitoring programs and biosecurity services, (vi) changes to the biosecurity industry,
More news about: Ginkgo Bioworks
Nov 13, 2025, 09:27 ET BiomEdit Announces USDA Finding of No Significant Impact Letter for Non-Antibiotic Poultry Biologic, Clearing Path to Field Safety Trials
BiomEdit BiomEdit, Inc., is an animal health microbial biotechnology company leveraging the power of the microbiome and synthetic biology to develop next-generation solutions for livestock and pet health. Founded in 2022, BiomEdit is backed by leading investors including Anterra
More news about: BiomEdit
Nov 11, 2025, 22:07 ET Concordia Shanghai Students Win Gold at International iGEM Competition in Paris
team earned a Gold Medal at the prestigious 2025 International Genetically Engineered Machine (iGEM) Competition in Paris, the world's premier synthetic biology event.
More news about: Concordia International School Shanghai
Nov 11, 2025, 09:00 ET Strategic Partnership Between Sanyou Bio and Yugong Bio to Accelerate Expansion in High-End Synthetic Enzyme Market
accelerating drug discovery. Yugong Bio is a national high-tech enterprise focusing on upstream molecular enzyme reagents for synthetic biology and their application solutions. The company possesses strong capabilities in enzyme molecular engineering and cell-free protein synthesis. Its
More news about: Sanyou Bio
Nov 10, 2025, 10:50 ET ERS Genomics and Dyadic Applied BioSolutions Sign CRISPR/Cas9 License Agreement
cell lines and animal models for drug screening, bioproduction of antibodies and therapeutic proteins, animal and agricultural biotechnology, synthetic biology, including production of enzymes, food ingredients, and bio-based chemicals. Current ERS licensees include GSK, Merck,
More news about: ERS Genomics
Nov 10, 2025, 08:45 ET Enzymit Achieves World's First Scaled Cell-Free Production of Hyaluronic Acid
Nov. 10, 2025 /PRNewswire/ -- Enzymit, a synthetic biology company pioneering cell-free biomanufacturing, in partnership with Cosun,
More news about: Enzymit
Nov 06, 2025, 16:05 ET Ginkgo Bioworks Reports Third Quarter 2025 Financial Results
business opportunities, including with respect to our solutions and tools offerings, (iv) the risk of downturns in demand for products using synthetic biology, (v) the uncertainty regarding the demand for passive monitoring programs and biosecurity services, (vi) changes to the biosecurity industry,
More news about: Ginkgo Bioworks
Nov 03, 2025, 08:00 ET Ginkgo Bioworks Awarded Project Agreement through BARDA's BioMaP-Consortium
This BARDA-supported initiative builds on Ginkgo Bioworks' track record in partnering with the U.S. government to provide ongoing leadership in synthetic biology, biomanufacturing innovation, and national biosecurity preparedness. This project has been funded in whole or in part with
More news about: Ginkgo Bioworks
Nov 03, 2025, 07:10 ET Partillion Launches Developer Kits, Powering Customer-Led Innovation on Nanovials
single-cell or multicell assays and select capture antibodies suited for applications in immunology, antibody discovery, cell therapy development, synthetic biology, and aging research. Partillion is also providing detailed documentation to help teams design and optimize their own assays.
More news about: Partillion Bioscience
Oct 31, 2025, 08:00 ET Ginkgo Bioworks and Bayer Extend Multi-Year Strategic Partnership to Accelerate Next Generation Biological Solutions for Agriculture
business opportunities, including with respect to our solutions and tools offerings, (iv) the risk of downturns in demand for products using synthetic biology, (v) the uncertainty regarding the demand for passive monitoring programs and biosecurity services, (vi) changes to the biosecurity industry,
More news about: Ginkgo Bioworks
Oct 31, 2025, 06:30 ET Agriculture Biotechnology Market worth $144.25 billion by 2030- Exclusive Report by MarketsandMarkets™
chemical dependence and boost resilience against climate-related stresses. Furthermore, increasing investments in AI-integrated biotechnology, synthetic biology, and sustainable input development are expanding market potential. Browse in-depth
More news about: MarketsandMarkets
Oct 28, 2025, 10:15 ET Cell-free Protein Synthesis Market worth $308.9 million by 2030 with 7.3% CAGR | MarketsandMarkets™
cell-free systems for complex protein production. The market also offers promising opportunities in commercial validation, vaccine development, synthetic biology, biosensor creation, and expanding into personalized medicine and therapeutic proteins. Adoption among research labs and pharmaceutical firms
More news about: MarketsandMarkets
Oct 24, 2025, 08:16 ET BiomEdit Awarded Nearly $2 Million from Bezos Earth Fund to Advance AI Model for Methane-Reduction Strategies in Cattle
BiomEdit BiomEdit is an animal health microbial biotechnology company leveraging the power of the microbiome and synthetic biology to develop next-generation solutions for livestock and pet health. Founded in 2022, BiomEdit is backed by leading investors Anterra Capital, Viking
More news about: BiomEdit
Oct 23, 2025, 08:00 ET Ginkgo Bioworks in Partnership with STRM.BIO and University of British Columbia in Project to Develop In Vivo CAR Therapies Under ARPA-H's EMBODY Program
business opportunities, including with respect to our solutions and tools offerings, (iv) the risk of downturns in demand for products using synthetic biology, (v) the uncertainty regarding the demand for passive monitoring programs and biosecurity services, (vi) changes to the biosecurity industry,
More news about: Ginkgo Bioworks
Oct 22, 2025, 11:16 ET UpTerra brings on new Chief Science Officer with Shiv Tiwari, Ph.D., former GreenVenus CEO and CTO
R&D. He's brought his scientific depth and leadership presence to companies including venture capital and private equity firm Third Security, synthetic biology business Intrexon, Mendel Biotechnology, and Corteva (DuPont Pioneer). Dr. Tiwari has lectured and taught at the University
More news about: UpTerra